Republican Allergy Center 1

1. The role of major allergens Art v 1 and Art v 3 in Artemisia pollen-induced asthma: a mouse model study
2. A recombinant Artemisia vulgaris pollen adjuvanted Art v 1 protein-based vaccine treats allergic rhinitis and bronchial asthma using pre- and co-seasonal ultrashort immunotherapy regimens in sensitized mice
3. Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria: A Cross-Sectional Study from Kazakhstan
4. Treatment of atopic dermatitis with upadacitinib: adcare single center experience
5. SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody
6. Evaluation of a SARS-CoV-2 spike protein ectodomain subunit vaccine with a squalene emulsion adjuvant in rodents and rhesus macaques
7. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters
8. Author Correction: An intranasal vaccine comprising SARS‑CoV‑2 spike receptor‑binding domain protein entrapped in mannose‑conjugated chitosan nanoparticle provides protection in hamsters (Scientific Reports, (2023), 13, 1, (12115), 10.1038/s41598-023-39402-0)
9. Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma
10. Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model
11. Intranasal monoclonal antibodies to mugwort pollen reduce allergic inflammation in a mouse model of allergic rhinitis and asthma
1